Agentix Corp.
0.0470-0.00 (-5.53%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCPK · AGTX · USD
Key Stats
Market Cap
1.88MP/E (TTM)
-Basic EPS (TTM)
-0.01Dividend Yield
0%Recent Filings
10-Q
Q1 FY2026 results
Agentix Corp. posted a Q1 FY2026 net loss of $185,824 for the quarter ended June 30, 2025, up 23% y/y from $150,717, driven by higher R&D spending at $100,000 (up 80% y/y) and professional fees of $82,625 (up 7% y/y), while G&A dipped slightly to $17,717. Operating loss widened to $200,342 (up 32% y/y), but other income including a $20,604 payable settlement and $15,140 forex gain cushioned the net hit; interest expense climbed to $21,226 on related-party debt. Cash drained to $4,412 after $118,371 in operating outflows, offset by $100,000 in financing proceeds, leaving liquidity razor-thin amid $3.3M liabilities dominated by related-party payables and a $343,000 note (extended to December 2025, 2% monthly interest post-grace). No revenue yet as this clinical-stage biotech pushes metabolic therapies. Cash barely holds.
10-K
FY2025 results
Agentix Corp. posted a net loss of $567,048 for FY2025 ended March 31, 2025, narrower than the $585,154 loss in FY2024, driven by a sharp drop in general and administrative expenses to $69,898 from $346,543 while research and development ticked up slightly to $180,987 from $175,268. No revenues emerged, as the clinical-stage biotech advances peripherally-restricted CB1 antagonists AGTX-2004 and AGTX-2003 toward human trials, with R&D efforts concentrated in Australia but no quarterly breakdowns disclosed in the 10-K. Cash dwindled to $4,477 amid $125,078 in operating outflows, offset by $100,000 in related-party debt proceeds, leaving liquidity razor-thin against $3.2 million in liabilities. No dividends or buybacks occurred. Substantial doubt clouds going-concern status without fresh funding. Regulatory hurdles could stall quarterly progress.
10-Q
Q3 FY2025 results
Agentix Corp. posted a Q3 FY2025 operating loss of $96,815, up from $15,846 a year earlier, driven by $23,287 in research and development costs that flipped from a $87,304 gain in Q3 FY2024 due to a one-time prior credit reversal, while professional fees fell 27% y/y to $56,632 and general expenses dropped 33% to $16,896. For the nine months ended December 31, 2024, the operating loss narrowed to $341,130 from $770,136 y/y, thanks to lower professional fees (down 37% to $197,942) and slashed G&A (down 83% to $52,550), though R&D rose slightly to $90,638; net loss widened to $385,280 from $582,156, with the gap to operating loss under 20% tied to $28,774 interest expense and $15,376 foreign exchange loss. Cash edged up to $8,273 from $6,535 y/y, fueled by $55,000 in related-party debt proceeds offsetting $82,020 operating outflow, while total liabilities climbed to $3.1M including a $198,000 note payable to Gray's Peak Capital (extended to June 30, 2025, secured by all assets). No revenue yet as the clinical-stage biotech advances metabolic disease therapies. Funding remains tight.
10-Q
Q2 FY2025 results
Agentix Corp narrowed its Q2 operating loss to $93,010 from $353,155 a year earlier, thanks to sharp cuts in professional fees, R&D, and G&A expenses, while net loss eased to $90,669 from $178,972 after a $12,185 foreign exchange gain offset higher interest costs. For the half-year, the operating loss shrank to $244,315 from $754,290, with net loss at $241,386 versus $588,530, though the prior period benefited from $198,371 in Australian R&D credits absent this year. Cash dipped slightly to $6,345 amid minimal operating inflows of $4,979, propped by $30,000 in related-party debt; the $173,000 mezzanine note to Gray's Peak Capital, secured by all assets and extended to January 1, 2025, bears 2% monthly interest post-initial period. No free cash flow disclosed in the 10-Q. Expenses are down, but funding remains tight. Competition in biotech therapeutics poses ongoing challenges.
10-Q
Q3 FY2025 results
Agentix Corp narrowed its Q3 FY2025 operating loss to $151K from $401K a year earlier, driven by sharp cuts in R&D consulting fees down 65% y/y to $56K and professional fees off 33% y/y to $77K, while general expenses plunged 85% y/y to $19K. No revenue yet, but cash burn eased dramatically, with operating cash use at just $2K versus $63K last year. The biotech holds $9K in cash against $2.9M liabilities, including a $163K related-party note due September 2024 at 2% monthly interest post-initial period, secured by all assets. Cash is razor-thin. Competition in metabolic disease therapeutics could squeeze funding prospects.
AAGH
America Great Health
0.00+0.00
ADTX
Aditxt, Inc.
0.11-0.02
AKRO
Akero Therapeutics, Inc.
54.00+0.00
ALT
Altimmune, Inc.
4.00-0.06
AURX
Nuo Therapeutics, Inc.
2.29+0.00
AVTX
Avalo Therapeutics, Inc.
18.04-0.34
LEXX
Lexaria Bioscience Corp.
0.96+0.01
NBTX
Nanobiotix S.A.
17.99+0.36
PTIX
Protagenic Therapeutics, Inc.
2.58-0.18
SGMT
Sagimet Biosciences Inc. - Seri
8.33+0.09